
    
      LYN-005-C-004 is a blinded, multiple-dose, randomized, parallel group, safety, tolerability
      and PK study of LYN-005 in subjects with a primary diagnosis of schizophrenia or
      schizoaffective disorder in general good health. Eligible subjects must be clinically stable
      and receiving a therapeutic dose of an approved oral antipsychotic drug for a minimum of 6
      weeks at the time of Screening. Enrolled subjects will be evaluated under steady-state
      conditions on commercially-available IR risperidone tablets and then assigned in blinded
      fashion either to LYN-005 weekly or continued encapsulated IR risperidone daily for 3 weeks
      to attain (or continue) steady-state exposure.
    
  